(E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one

Skin sensitisation

Administrative data

Endpoint:

skin sensitisation: in vivo (LLNA)

Type of information:

experimental study

Adequacy of study:

key study

Study period:

From February 14 to March 24, 2001

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

comparable to guideline study with acceptable restrictions

Remarks:

GLP study conducted similarly to OECD 429 Guideline with deviations: no ear thickness measurement; no range-finding test was performed. However, no sign or irritation or systemic toxicity were observed at the concentration giving a SI above 3.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2001

Report date:

2001

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)

Deviations:

yes

Remarks:

no ear thickness measurement, no range finding test performed.

Principles of method if other than guideline:

Not applicable

GLP compliance:

yes

Type of study:

mouse local lymph node assay (LLNA)

Test material

Test material information

Constituent 1

Reference substance name:

(E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one

EC Number:

246-430-4

EC Name:

(E)-1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-buten-1-one

Cas Number:

24720-09-0

Molecular formula:

C13H20O

IUPAC Name:

1-(2,6,6-trimethylcyclohex-2-en-1-yl)but-2-en-1-one

Test material form:

liquid

Details on test material:

- Name of test material (as cited in study report): ST 48 C 00
- Physical state: Liquid
- Storage condition of test material: Stored at room temperature.

In vivo test system

Test animals

Species:

mouse

Strain:

other: CBA/J Hsd

Sex:

female

Details on test animals and environmental conditions:

TEST ANIMALS
- Source: Harlan Sprague-Dawley, Inc., Indianapolis, IN.
- Age at study initiation: 6-8 weeks
- Weight at study initiation: 15.5-20.9 g (mean body weight: 18.6 g)
- Housing: Animals were housed individually in plastic shoebox-style cages.
- Diet: Purina Rodent Chow 5002, ad libitum
- Water: Tap water, ad libitum
- Acclimation period: 8 days

ENVIRONMENTAL CONDITIONS
- Temperature: 66-78 °F
- Humidity: 22-66 %
- Photoperiod: 12 h dark/12 h light

IN-LIFE DATES: From: February 14, 2001 To: March 24, 2001.

Study design: in vivo (LLNA)

Vehicle:

acetone/olive oil (4:1 v/v)

Concentration:

0.1, 0.25, 0.5, 1.0, 2.5, and 5 % in 4:1 acetone/olive oil

No. of animals per dose:

6 females/dose

Details on study design:

MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: Local Lymph Node Assay
- Criteria used to consider a positive response: A substance is considered a sensitiser if at least one concentration of the test material results in a statistically significant 3-fold or greater stimulation index (SI).

TREATMENT PREPARATION AND ADMINISTRATION:
- The vehicle and dilutions of the control and test materials were prepared on the bench top daily, prior to dosing. All suspensions were mixed by vortexing. 25 µL of control or test material was applied to the dorsum of each ear using a calibrated Finnpipet daily for three consecutive days. Animals were not treated on Days 4 and 5. On Day 6, animals were injected i.v. in the lateral tail vein with 0.25 mL containing 2 µCi of 125I-labelled Iododeoxyuridine, and 10^-5 M FuDR in phosphate buffered saline (PBS). Approximately 5 h later, animals were euthanized by CO2 asphyxiation and the auricular lymph nodes were excised. The nodes were dissociated using the frosted ends of glass slides. The cell suspension was washed with Hanks' Balanced Salt Solution (HBSS) and then with PBS, prior to being resuspended in 5 % tricholoroacetic acid (TCA; LabChem lot # 0322-11) and refrigerated at approximately 4 °C. Approximately 18 h later the cells were centrifuged and resuspended in fresh 5 % TCA. The radioactivity was measured using a gamma counter (Packard Instruments).

OTHERS:
- The results from each cell suspension counted on the gamma counter were recorded in counts per minute (CPM). The CPM were converted to disintegrations per minute (DPM) by dividing by the gamma counter efficiency and multiplying by 100. After the DPM values had been calculated, the mean "blank" DPM was subtracted from each animal DPM to obtain corrected DPM values. The mean corrected DPM and standard error of the mean (SE) were determined for each group. The stimulation index (Sl) was then calculated by dividing the treated group mean DPM by the control (vehicle) group mean DPM.

Positive control substance(s):

other: Isoeugenol - at 0.5 % and 5 % in 4:1 acetone/olive oil

Statistics:

- To test if the compound was a sensitizer, a one-sample t test was performed for testing if the individual untransformed SI values of each dose level of each compound were different than 3.0.
- The natural log transformed DPM values for each test material concentration were compared against vehicle by first performing a Bartlett's Chi-Square test for variance homogeneity. If this was found to be non-significant, a one-way analysis of variance was used using dose (concentration) - i.e., 0.1, 0.25, 0.5, 1.0, 2.5 and 5 %. If this was found to be significant, then a Dunnett's t test was performed using an alpha of 0.05.
- If the Bartlett's Chi-Square was found to be significant, non-parametric analyses (specifically a Kruskal-Wallis test) were performed. If this was found to be significant, then a Jonckheere's-Terpera test was performed for dose-dependent trends.
- A confirmatory analysis was performed against the known standard isoeugenol at two concentrations, 0.5 and 5 % using the above methods.
- A fitted quadratic equation was used to determine the concentration of test material required to elicit a stimulation index of 3 (EC3). The data from the concentrations tested were fit using a quadratic equation (a linear term and a square term of the concentration).
- A fitted linear equation was used to determine the concentration of isoeugenol required to elicit a stimulation index of 3 (EC3) as only 3 doses (0, 0.5 and 5 %) of isoeugenol were tested.
- All calculations were performed using Microsoft Excel and SAS, version 6.12. PROCs GLM, FREQ, NPAR1WAY and MEANS were utilized.

Results and discussion

Positive control results:

Only 5 % concentrations of isoeugenol resulted in group SI statistically significantly greater than 3 and statistical analysis (one-sample t tests). A fitted linear regression yielded an EC-3 of 1.8 % for isoeugenol.

In vivo (LLNA)

Results

Results 1

Parameter:

SI

Value:

0.4

Test group / Remarks:

0.1 % test group

Results 2

Parameter:

SI

Value:

0.8

Test group / Remarks:

0.25 % test group

Results 3

Parameter:

SI

Value:

1.1

Test group / Remarks:

0.5 % test group

Results 4

Parameter:

SI

Value:

1.5

Test group / Remarks:

1 % test group

Results 5

Parameter:

SI

Value:

1.9

Test group / Remarks:

2.5 % test group

Results 6

Key result

Parameter:

SI

Value:

4.4

Test group / Remarks:

5 % test group

Results 7

Key result

Parameter:

EC3

Value:

3.3

Any other information on results incl. tables

- No irritation or other adverse toxic effects were noted in any of the mice used in this study, and there were no animal deaths in any of the groups.  

- The highest dose (5 %) of the test article had an SI = 4.4. A one-sample t test on the untransformed SI values indicated that this SI of 4.4 was statistically significant. All the other doses tested (0.1, 0.25, 0.5, 1 and 2.5 %) had SI values less than 3.0.

- Mean disintegrations per minute (DPM) for vehicle, 0.1, 0.25, 0.5, 1, 2.5 and 5 % were 8.6, 3.7, 6.9, 9.53, 13, 16.3 and 37.9, respectively.

- The calculated EC-3 for test material using a fitted quadratic equation was 3.3 %.

Applicant's summary and conclusion

Interpretation of results:

Category 1B (indication of skin sensitising potential) based on GHS criteria

Conclusions:

Under the test conditions, test material is classified in Category 1B for skin sensitisation according to the annex VI of the Regulation EC No. 1272/2008 (CLP) and to the GHS.

Executive summary:

In a Local Lymph Node Assay (LLNA) conducted similarly to the OECD test guideline No 429 and in compliance with GLP, groups of female CBA/J Hsd mice (6 females/group) were topically applied with test material at the dose concentrations of 0.1, 0.25, 0.5, 1, 2.5 and 5 % final concentration in 1:4 acetone:olive oil to the dorsal surface of both ears (25 µL/ear) daily for three consecutive days. A vehicle control group was treated with 1:4 acetone:olive oil alone and a positive control group was treated with isoeugenol at the dose concentration of 0.5 and 5 % in acetone:olive oil (4:1) in same manner to confirm the sensitivity and reliability of the test method. The animals were allowed to rest without dosing on Days 4 and 5. On Day 6, animals were injected intravenously with 125I- labeled luDR to label proliferating cells. 125I-incorporation was quantified using a gamma counter and disintegrations per minute (DPM) and stimulation index (Sl) were calculated for each dose group.

The positive control, Isoeugenol gave a SI of 7.2, when tested at 5 % in 4:1 acetone/olive oil. The test system was therefore considered to be valid.

No mortality, irritation or other adverse toxic effects were noted in any of the animals. Mean DPM for vehicle, 0.1, 0.25, 0.5, 1, 2.5 and 5 % were 8.6, 3.7, 6.9, 9.5, 13, 16.3 and 37.9, respectively. Stimulation Index (SI Value) calculated for test material treated groups was found to be 0.4, 0.8, 1.1, 1.5, 1.9 and 4.4 for the dose concentrations of 0.1, 0.25, 0.5, 1, 2.5 and 5 %, respectively. The highest dose (5 %) of the test article had an SI = 4.4. A one-sample t test on the untransformed SI values indicated that this SI of 4.4 was statistically significant. All the other doses tested (0.1, 0.25, 0.5, 1 and 2.5 %) had SI values less than 3.0. The calculated EC-3 for test material using a fitted quadratic equation was 3.3 %.

Under the test conditions, test material is classified as a skin sensitiser (Category 1B) according to the annex VI of the Regulation EC No. 1272/2008 (CLP) and to the GHS.

This study is considered as acceptable and satisfies the requirement for sensitisation endpoint.